Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Communiqués de presse de la société ASTRAZENECA
11/17ASTRAZENECA :  Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevatio..
BU
11/17ASTRAZENECA : Consistent Effects of FARXIGA in Heart Failure Patients With Reduc..
BU
11/15ASTRAZENECA : Qtrilmet approved in the EU for treatment of T2D
AQ
11/14ASTRAZENECA : Launches Diabetes Can Break Your Heart
BU
11/14MERCK AND : US FDA accepts regulatory submission for selumetinib in neurofibroma..
AQ
11/11ROXADUSTAT POOLED ANALYSES : no increased CV risk
PU
11/08ASTRAZENECA : Roxadustat Phase III programme pooled analyses showed positive eff..
PU
11/08ASTRAZENECA : Roxadustat Phase III Program Pooled Analyses Showed Positive Effic..
BU
11/08ASTRAZENECA : New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced t..
BU
11/08ASTRAZENECA : Roxadustat significantly increased haemoglobin
PU
11/07ASTRAZENECA : Roxadustat significantly increased haemoglobin levels for chronic ..
PU
11/07ASTRAZENECA : Roxadustat Significantly Increased Hemoglobin Levels for Chronic K..
BU
11/06ASTRAZENECA : CALQUENCE® Data To Show Improved Progression-Free Survival In Phas..
BU
11/06ASTRAZENECA : Calquence data to show improved progression-free survival in Phase..
PU
11/06ASTRAZENECA : Calquence data to show improved progression-free
PU
11/06ASTRAZENECA : announces three large-scale initiatives in China to advance global..
PU
11/01ASTRAZENECA : Upcoming events February 14 2020 Full-Year 2019 Results
PU
10/30ASTRAZENECA : to present pivotal roxadustat Phase III data at the American Socie..
PU
10/30ASTRAZENECA : divests rights to Seroquel and
PU
10/30ASTRAZENECA : divests rights to Seroquel and Seroquel XR in Europe and Russia
AQ
10/28ASTRAZENECA : IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Diseas..
BU
10/28ASTRAZENECA : Imfinzi and Imfinzi plus tremelimumab delayed disease progression ..
PU
10/28ASTRAZENECA : Imfinzi and Imfinzi plus tremelimumab delayed
PU
10/24ASTRAZENECA : 3Q Earnings Snapshot
AQ
10/24ASTRAZENECA : Year-to-date and Q3 2019 Results
PU
10/24ASTRAZENECA : year-to-date and Q3 2019 results
AQ
10/22ASTRAZENECA : commits $35m to help young people tackle the threat of non-communi..
PU
10/21ASTRAZENECA : FARXIGA Approved in the US to Reduce the Risk of Hospitalization f..
BU
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of hospitalisation f..
PU
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of
PU
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of hospitalisationfo..
AQ
10/17ASTRAZENECA : Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment o..
BU
10/17ASTRAZENECA : Trastuzumab deruxtecan granted FDA Priority Review for treatment o..
PU
10/17ASTRAZENECA : Trastuzumab deruxtecan granted FDA Priority Review
PU
10/07ASTRAZENECA : Launches Signature STEM Program to Empower Students to Live Health..
BU
10/04ASTRAZENECA : FASENRA® (benralizumab) Approved in the US for Self-administration..
BU
10/04ASTRAZENECA : Fasenra approved in the US for self-administration in a new pre-fi..
PU
10/04ASTRAZENECA : Fasenra approved in the US for self-administration
PU
10/04ASTRAZENECA : Fasenra approved in the US for self-administrationin a new pre-fil..
AQ
10/01ASTRAZENECA : divests rights for Losec to Cheplapharm
PU
10/01ASTRAZENECA : divests rights for Losec to Cheplaphar
AQ
10/01ASTRAZENECA : Update on US regulatory review of PT010 in COPD
AQ
09/30ASTRAZENECA : Lynparza more than doubled the time without radiographic disease p..
PU
09/30ASTRAZENECA : LYNPARZA (olaparib) More Than Doubled the Time Without Radiographi..
BU
09/30ASTRAZENECA : Lynparza more than doubled the time without
PU
09/30ASTRAZENECA : Lynparza improved the time women lived without
PU
09/30ASTRAZENECA : Tagrisso is the only 1st-line treatment for EGFR-
PU
09/30ASTRAZENECA : Lynparza improved the time women lived without disease progression
AQ
09/30ASTRAZENECA : Tagrisso is the only 1st-line treatment for EGFR-mutated non-small..
AQ
09/28ASTRAZENECA : LYNPARZA (olaparib) Improved the Time Women Lived Without Disease ..
BU
09/28ASTRAZENECA : Tagrisso is the only 1st-line treatment for EGFR-mutated non-small..
PU
09/28ASTRAZENECA : Lynparza improved the time women lived without disease progression..
PU
09/27INNATE PHARMA : SA - Monalizumab to advance to Phase III in head and neck cancer
AQ
09/26ASTRAZENECA : BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent ..
BU
09/25ASTRAZENECA : to present next wave of science in respiratory disease at ERS Inte..
PU
09/23ASTRAZENECA : Qtrilmet recommended for approval in EU by CHMP for the treatment ..
PU
09/23ASTRAZENECA : Qtrilmet recommended for approval in EU by CHMP
AQ
09/18IRONWOOD PHARMACEUTICALS : AstraZeneca amends collaboration with Ironwood for Li..
AQ
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
PU
09/18ASTRAZENECA : amends collaboration with Ironwood
PU
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
AQ
09/16ASTRAZENECA : redefines cancer treatment with practice-changing data at ESMO 201..
PU
09/16ASTRAZENECA : FDA grants Fast Track designation for Farxiga in heart failure
PU
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both significant survival b..
PU
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both
PU
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both significant survival b..
AQ
09/04ASTRAZENECA : Tagrisso approved in China as a 1st-line treatment for EGFR-mutate..
PU
09/04ASTRAZENECA : Tagrisso approved in China as a 1st-line treatment
PU
09/04ASTRAZENECA : Tagrisso approved in China as a 1st-line treatment for EGFR-mutate..
AQ
09/02ASTRAZENECA : Brilinta reduced the risk of cardiovascular events
PU
09/02ASTRAZENECA : Detailed results from Phase III DAPA-HF trial
PU
09/02ASTRAZENECA : Brilinta reduced the risk of cardiovascular events in patients wit..
AQ
09/02ASTRAZENECA : Detailed results from Phase III DAPA-HF trial showed Farxigasignif..
AQ
09/01ASTRAZENECA : Brilinta reduced the risk of cardiovascular events in patients wit..
PU
09/01ASTRAZENECA : BRILINTA Reduced the Risk of Cardiovascular Events in Patients Wit..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASTRAZENECA